

Dr. Di (Andy) Ai, MD, PhD, FCAP, is an academic surgical pathologist currently serving as Assistant Professor of the Department of Anatomic Pathology at The University of Texas MD Anderson Cancer Center. He is a board-certified pathologist with subspecialty expertise in breast pathology, supported by fellowship training in both breast pathology and oncologic surgical pathology at MD Anderson. Dr. Ai's academic career spans leading institutions including Emory University, UTHealth Houston and MD Anderson, reflecting a strong commitment to excellence in clinical service, research, education, and professional leadership.



Dr. Ai has maintained an active and sustained involvement with the Chinese American Pathologists Association (CAPA) since 2016 and is a lifetime member since 2021. His leadership within CAPA includes service as Director of the Immunohistochemistry Subcommittee, Director/ Associate director of the IT and Website Subcommittee, as well as Associate Director of the Membership Subcommittee. In recognition of his dedicated contributions, Dr. Ai received the CAPA Service Award in 2024. These roles have provided him with firsthand experience in organizational governance, strategic planning, digital infrastructure, and member engagement—skills directly relevant to service on the CAPA Board of Directors.

Academically, Dr. Ai has a strong national and international profile. He has authored several book chapters and 35 publications in high-impact journals, such as *Modern Pathology*, *Histopathology*, *Breast Cancer Research and Treatment* and *Proceedings of the National Academy of Sciences of the United States of America*, with particular focus on biomarkers, breast pathology and basic/translational research. He also published nearly 40 abstracts presented at regional, national and international conferences, including 5 oral presentations, reflecting sustained scholarly productivity and active engagement with the pathology community. He currently serves as Co-Investigator on a NIH-funded R01 grant, demonstrating success in funded research. His work bridges translational research, diagnostic practice, and clinical outcomes.

Dr. Ai is also deeply committed to education and mentorship. He is an active lecturer for pathology residents, regularly supervises undergraduates, medical graduates and research trainees. His teaching philosophy emphasizes rigor, clarity, and commitment to mentorship, which expands to foreign medical graduates seeking pathology training in the United States. His mentees have been admitted into medical school and residency program in the past few years. He also participates in medical school admissions and academic service committees.

With a career that integrates clinical excellence, scholarly productivity, organizational leadership, and service to the Chinese pathology community, Dr. Ai will bring both vision and practical experience to the CAPA Board of Directors. He is dedicated to advancing CAPA's mission of professional development, academic collaboration, and advocacy for Chinese pathologists nationwide.

Dr. Liam Chen is a Professor in the University of Minnesota Medical School and serves as Director of the Neuropathology Division and Director of the Neuropathology Fellowship Program. He also provides clinical leadership as Director of the Minnesota David Tomassoni Biorepository Center and Director of the Immunohistochemical Laboratory at M Health Fairview.

Dr. Chen earned his medical degree (Bachelor of Medicine) at Shandong University, followed by a PhD at the University of Alberta. He completed postdoctoral training at Harvard Medical School, anatomic pathology residency at Brigham and Women's Hospital, and fellowships in molecular genetic pathology and neuropathology at Harvard Medical School. He is board certified in anatomical pathology, neuropathology, and molecular genetic pathology. Dr. Chen's scholarly work spans translational neuropathology, molecular diagnostics, neurodegeneration, and CNS tumor pathology. His research has been supported by both federal and foundation funding. Dr. Chen has over 100 scholarly works including research articles, reviews, and book chapters, and have received over more than 15,000 citations. He is the chief editor for journals including *Diagnostics* and *Journal of Neurology Research*. In addition, Dr. Chen serves as a member in multiple editorial boards, grant evaluation and review bodies including NIA/NIH and Department of Defense.

Dr. Chen is a life member of CAPA and has served as the Chair of Neuropathology Subcommittee since 2020.



Dr. Huihua Li is an Assistant Professor at the Department of Pathology, Duke University Medical Center. He practices Thoracic/Pulmonary, Cardiovascular, and Autopsy Pathology. Dr. Li completed his residency in a combined Anatomic and Clinical Pathology at the University of Wisconsin-Madison (2018-2022), followed by a dedicated Thoracic and Surgical Pathology Fellowship at the University of Chicago (2022-2023). Before his residency, Dr. Li pursued PhD and postdoctoral training at the University of Pittsburgh Medical Center where his research focused on acute lung injury, idiopathic pulmonary fibrosis, and lung immunology; these efforts had resulted in two NIH R01 grants.



Dr. Li currently serves as an Associate Director of Duke Autopsy service and will step into the Director role on January 1, 2026. He also serves as a member of Duke University Biosafety Committee (IBC) and Biosafety Review Committee (IBRC). As a dedicated educator, Dr. Li has taught Pathology courses to Duke medical students since he joined Duke in 2023. He has been actively involved in Duke Pathology Residency interviews annually, and he enjoys working with residents and serving as a mentor.

Dr. Li is a member of the College of American Pathologists (CAP) Immunohistochemistry Committee, he also plays active roles in national pathology societies including Pulmonary Pathology Society, Society for Cardiovascular Pathology, and the International Mesothelioma Panel. Dr. Li is enthusiastic about research. As a primary investigator, he received a research grant from the Lung Cancer Initiative for his project focusing on “CXCR2 Expression in Lung Neuroendocrine Neoplasms” (07/2024-12/2025). Dr. Li has published 4 book chapters as a first author and over 30 peer-reviewed publications and numerous conference abstracts. He was invited to review manuscripts for prestigious journals such as *Archives of Pathology & Laboratory Medicine*, *International Journal of Surgical Pathology*, *Journal of Clinical and Translational Pathology*, and *Scientific Reports*, etc.

Dr. Li has been actively engaged in CAPA activities. He serves as a member of CAPA Award Committee and Thoracic Subcommittee. Dr. Li presented a lecture entitled “Morphologic Spectrum of Cardiac Diseases: Insights from Explanted and Post-Mortem Hearts” at the 11th CAPA Diagnostic Course (09/2025) at Orlando, FL as well as a lecture entitled “Mesothelioma and Mesothelial Tumors” at the 9th CAPA Diagnostic Course (09/2023) at Denver, CO. His other CAPA activities included lecturing in CAPA’s online education program and in Zhejiang/CAPA Thoracic Pathology Symposium.

Dr. Li is thrilled to contribute more and make the best effort to serve all CAPA members. He looks forward to the opportunity to work with other leadership members to polish CAPA pathologists’ diagnostic skills by strengthening the educational activities, to enhance CAPA’s influence by collaborating more and deeply with other organizations, and to prompt every member’s success within and beyond CAPA.

Dr. Qun Wang is an Associate professor in the Department of Pathology at Emory University School of Medicine. She is deeply committed to education, service, and research, and has been actively engaged in professional leadership at the local, national, and international levels.



At Emory, Dr. Wang serves on several institutional committees, including the Pathology Education Committee, Pathology QA Committee, Digital Pathology Committee, and the Emory Winship Network Cancer Committee. She has mentored numerous trainees on research projects that have resulted in national and international presentations and peer-reviewed publications. Dr. Wang has authored more than 100 professional works, including peer-reviewed articles, abstracts, and case studies, and has presented extensively at national and international conferences. Her contribution to medical education, clinical service, and research has been recognized through multiple honors, including Emory School of Medicine Educator Appreciation Day (2023- 2025), National Doctors' Day, (2025), the Research Award for the Global Ring Study for HER2 IHC Testing in Breast Cancer (2023), Researcher Appreciation Day (2025), and the 2024 Departmental Outstanding Service Award.

Nationally and internationally, Dr. Wang contributes to the American Society of Cytopathology (ASC) as a member of the Membership Committee and the Case Study Committee, where she authors and reviews educational content. She also serves on the Papanicolaou Society of Cytopathology (PSC) Research Award Committee, reviewing and scoring trainee-authored abstracts submitted to the USCAP Annual Meeting, assisting in the selection of the “First-place” and “Second place” awards. In addition, she is a mentor in the ASC Dyadic Mentorship Program under the Mentoring and Pathway Committee.

Dr. Wang is also committed to global cancer education through her involvement with the Partnership of Emory and Allies for Cancer and Education (PEACE), where she serves as a lecturer, moderator, and member of the Annual Symposium Planning Committee.

Regionally, Dr. Wang holds multiple leadership roles within the Georgia Association of Pathology (GAP), including Board Member, Chair of the Membership Committee, and Co-Chair of the Education Committee. She also serves on the GAP Annual Meeting Organizing Committee and Abstract Review Board, supporting professional development for pathologists across Georgia.

Dr. Wang has been actively engaged in CAPA initiatives and strongly supports its mission. She currently serves as Chair of the CAPA Cytopathology Subcommittee and developed the 2026 CAPA Cytopathology Online Lecture Series (Cytopathology Bootcamp). She has also served on the CAPA Education Committee, the 11th CAPA Diagnostic Course and CAPA-CAP Companion Meeting Organizing and Scientific Committees (2025), and as a moderator for the 2025 CAPA-ASC Companion Meeting. Additionally, she was an invited faculty speaker for the 8th and 10th CAPA Diagnostic Courses.

Dr. Yu Yang earned her M.D. from Weifang Medical University and an M.S. from Peking University Health Science Center. She completed an Anatomic and Clinical Pathology residency at Wake Forest Baptist Medical Center, where she served as chief resident, followed by a hematopathology fellowship at Vanderbilt University Medical Center. She is a board-certified hematopathologist, a Clinical Assistant Professor, and the Medical Director of the Pathlabs Core Lab at the University of Florida.



An active member of the Chinese American Pathologists Association (CAPA) since 2020, Dr. Yang serves on the CAPA Newsletter Committee (since 2022), has been faculty at CAPA's 9th Annual Meeting (2023), and was an invited lecturer at the 11th CAPA Annual Diagnostic Course (2025). She also engages regularly in CAPA's weekly lectures, underscoring her sustained commitment to the society's educational mission.

Her leadership development includes the College of American Pathologists Engaged Leadership Academy and the University of Florida College of Medicine Leadership Academy, experiences that strengthened her skills in communication, collaboration, and strategic planning.

With a blend of clinical expertise, laboratory leadership, and dedicated service to CAPA's mission, she is prepared to be an effective member of the Board of Directors and contribute to the organization's continued success.

Dr. Huina Zhang, MD, PhD, is an Associate Professor of Pathology and Director of gynecologic pathology in the Department of Pathology and Laboratory Medicine at the University of Rochester Medical Center, with subspecialty expertise in breast and gynecologic pathology. I received MD and PhD degrees in China, followed by residency training in Combined Anatomic and Clinical Pathology at Loma Linda University Medical Center. I subsequently completed a clinical instructorship in breast and gynecologic pathology at Magee-Womens Hospital of the University of Pittsburgh Medical Center.



I have been actively and consistently engaged in professional service within national and international pathology societies. Since 2023, I have served as faculty for the College of American Pathologists (CAP) Multidisciplinary Breast Pathology Program and has been a member of the Pathologist Advisory Group for the CAP Multidisciplinary Breast Pathology Education Program since 2024. I also served on the Abstract Review Board for the Breast Pathology Section of the United States and Canadian Academy of Pathology (USCAP) between 2021 and 2024. In addition, since 2021, I have held multiple roles within the Chinese American Pathologists Association (CAPA), including serving as a member, co-chair, and chair of the Breast Pathology Committee, Immunohistochemistry Committee, and Awards Committee. I have also contributed to several institutional committees at the University of Rochester.

Beyond committee service, I serve as a section editor or editor for several peer-reviewed journals and as an ad hoc reviewer for more than 20 pathology- and breast cancer-related journals. Additionally, I am actively engaged in pathology education and have delivered more than 40 invited lectures at the institutional, national, and international levels.

My research interests focus primarily on HER2 in breast and gynecologic malignancies. I have authored nearly 100 peer-reviewed publications and contributed multiple book chapters, reflecting my sustained scholarly productivity and impact in the field.